Introduction
At the Washington DC Pharmacogenomics in Drug Development and Regulatory Decision-Making: Workshop III -Three Years of Promise, Proposals and Progress on Optimizing the Benefit/Risk of Medicines 1 (11-13 April 2005), Track 2 focused on co-development of therapeutic drug and diagnostic products. Many of the issues were derived from a preceding workshop (July 29, 2004 ) also held in Washington DC. 2 Both workshops were organized by the Food and Drug Administration (FDA) in conjunction with the Drug Information Association (DIA), Pharmaceutical Research and Manufacturers of America (PhRMA), the Biotechnology Industry Organisation (BIO) and the Pharmacogenetics Working Group (PWG) to discuss pharmacogenomics in drug development and regulatory decision making. During the July 2004 workshop, a complex discussion took place on the co-development of a therapeutic drug with a diagnostic device for use in selection of a drug in specific patient groups for specific indications. Speakers from the FDA and both the drug and diagnostic industries participated in the meeting, and took part in both presentations and panel discussions. At the conclusion of the 2004 meeting, Dr Larry Lesko (Director of FDA's Office of Clinical Pharmacology and Biopharmaceutics and leader of the Agency's initiative on pharmacogenomics) confirmed that the FDA would take industry's concerns into serious consideration. 2 He further stated that a cross-functional FDA team, with representatives from the drug and diagnostic review divisions, as well as the Office of Combination Products would work to develop a draft guidance in this complex field.
In advance of the guidance, the FDA released a draft concept paper on April 7, 2005, 3 shortly before the April 2005 workshop was to convene. Track 2 of the workshop, as reported here, was a forum for initial discussion of the concept paper with session presentations from the FDA on the content of the concept paper 4 followed by industry's initial reactions. 5 Advance copies of the presentation materials were not available; therefore, audience participation reflected early review of the concept paper and reactions to the presentation and perspectives from this and previous meetings. After the workshop, formal commentaries on the co-development concept paper were submitted by several trade associations (e.g., PhRMA, AdvaMed, American Association for Clinical Chemistry) and individual companies to the FDA's Docket No. 2004N-0279. A brief summary of the key features of the draft concept paper, the discussion in Track 2 of the April, 2005 meeting and highlights of the industry comments submitted to the docket are provided below.
The draft drug diagnostic co-development concept paper 3, 4 The draft concept paper, released on April 7, 2005, 3 describes the Agency's preliminary thoughts on how to prospectively co-develop a drug or biological therapy (drugs) and a device (test) in a 'scientifically robust and efficient way'. The FDA noted that these concepts do not constitute guidance but reflect perspectives under consideration. Although a detailed description of its content is beyond the scope of this article, the concept paper makes the point that while the use of diagnostic tests in conjunction with drug therapy is well established (e.g., estrogen receptor hormones, Her 2 neu DNA and protein, EGFR protein), new technology has enabled the development of pharmacogenomic in vitro diagnostic tests to identify inter-individual variability in drug responses, both in efficacy and safety. Such tests might be used to guide drug selection and target therapy to selected patient subsets. Distinctions are made in the paper between cases in which the use of the test is mandatory (i.e., both the drug and diagnostic are necessary) in making a therapeutic decision for the selection of a drug for a specific patient and cases in which the test may be informative but not mandatory. In the latter situation, for example, testing may be helpful in understanding the mechanisms and determining how to enrich or select populations to study. The principles discussed in the concept paper are also relevant to pharmacogenomic testing for dosing determination of drugs.
In the concept paper, 'co-development' refers to considerations when both the therapeutic drug and diagnostic test are necessary for the intended clinical indication. These products may raise development issues that affect both the drug and the test products. (Co-development products may or may not meet the regulatory definition of a combination product under 21 CFR 3.2(e).) The paper presents information in five areas: regulatory considerations, analytical test validation, clinical test validation, clinical test utility and labeling. Each of these areas addresses prospective codevelopment of a single test in conjunction with a single drug.
Regulatory considerations focus on the need for industry and the FDA to include both drug and device firms and Center for Drug Evaluation and Research (CDER) and Center for Devices and Radiological Research (CDRH) in the Figure 1 The drug-test co-development process describing key steps during development. From the FDA draft concept paper on drug diagnostic co-development, April, 2005.
The drug diagnostic co-development concept paper LM Hinman et al development discussions. The paper contains two diagrams ( Figures 1 and 2 ), which are included in this report for reference. Figure 1 highlights key steps in the co-development process that relate to various sections of the concept paper and the type of issues that may be considered during development. For example, the process begins with basic research, target selection and validation and ends with clinical validation for the use of the drug and the diagnostic test. Figure 2 illustrates the parallel formal Industry-FDA interactions that would occur with both the drug and diagnostic review processes when two investigational applications are used. For example, the figure identifies formal meetings that would occur in the investigational development for the IDE(investigational device exemption) applications and the drug (IND -investigational new drug). These interactions would be with one or more of the following FDA centers: CDER, Center for Biologic Evaluation and Research (CBER) and CDRH. The section on regulatory considerations also contains a list of questions that a sponsor might want to consider in planning early FDA discussions: for example, what analytical and clinical data are needed to support retrospective development and validation of the diagnostic test, or what is the most appropriate regulatory pathway for the proposed project.
Analytical test validation
The paper provides general recommendations and preliminary details on the type of analytical and clinical validation information that may be expected for the co-developed diagnostic test. The paper recognizes that a key hurdle for prospective co-development relates to the availability of pharmacogenomic samples. There are recommendations for the device description, analytical studies, software and instrumentation, feasibility studies and considerations for test changes during the late stages of co-development. The paper includes examples of the type of information that may be necessary to submit; for example, estimates of clinical test performance and test quality measurements, primarily from the diagnostic perspective.
Clinical test validation
The section on clinical test validation and statistical considerations focuses mainly on evaluation of clinical performance of the test and setting test parameters when the test will be used to select patients to receive or avoid a drug, or to stratify patients in some manner; for example, in the context of the intended clinical outcome. It provides information on statistical considerations in co-development. Also, there is a related section on pre-clinical pilot feasibility studies.
Clinical utility
The section on clinical utility discusses various clinical trial design considerations to help minimize bias and to assure that results of the trials address the primary study hypothesis. The amount of clinical trial data required to verify utility will differ depending on prior knowledge of pathophysiology involved, the magnitude of differences in outcome, and the extent of previous relevant clinical experience. Clinical development considerations were similar to expectations to support other clinical hypotheses (i.e., the end points that are used to establish safety and effectiveness of the drug and diagnostic test should reflect the end points used to establish the test population selection). Also, this section addresses statistical issues in the context of the therapeutic and the diagnostic. The FDA also notes that pre-specified retrospective clinical utility studies utilizing previously collected pharmacogenomic samples may be possible. In addition, the paper discusses data collection, data standards, statistical issues and information that would be submitted to allow an FDA audit of the clinical and other material.
The recommendations in this section are based on the premise of a prospective co-development model; for example, The drug diagnostic co-development concept paper LM Hinman et al the test and drug go through the early stage of development in parallel, emerging from early development together to be used in conjunction in pivotal trials. This proposed pathway indicates that clinical utility should be established for the test with the specific drug. As such, the FDA would expect concurrent reviews and approval of the therapeutic drug and diagnostic test to achieve the intended indication of both products. The co-review process could be facilitated in some cases by the Office of Combination products (OCP).
The drug diagnostic co-development concept paper concludes with a glossary of terms, examples of device descriptors and examples of study design issues. Labeling of the drug and diagnostic (e.g., what information should be in each label or both) was not addressed in the concept paper. At a recent advisory committee for pharmaceutical science-clinical pharmacology subcommittee meeting, 7 however, the FDA presented general recommendations for when and where the pharmacogenomic information will be included in the drug/biologics or device labeling.
Industry feedback/discussion on the draft concept paper -April, 2005 meeting 5, 6 During the 45-min workshop session, the audience provided its feedback on the presentation on the co-development concept paper. Industry's critical concerns on the concepts reflected regulatory and procedural issues previously identified in the July, 2004 workshop and in other informal discussions between the FDA and industry. These included the following points and recommendations for information to include in a subsequent FDA draft guidance:
A. Practical concerns Overall, industry expressed concern that the scope of the concept paper (the single drug/test concept) may have limited applicability. The more common industry practice is for non-parallel drug and test development. Diagnostic test development programs often do not begin until a validated biomarker has been identified and its clinical potential has been examined in early exploratory studies. As such, industry indicated that more information was needed on the FDA's expectations on the co-development process to assist firms in developing partnering strategies for the products. For example, what timing and procedures would be useful for interaction of the sponsor (or sponsors if the diagnostic and drug sponsors are not the same) with CDER/ CBER and CDRH. Is it expected that the diagnostic manufacturer will begin to participate in the FDA discussions as early as the time of a voluntary genomic data submissions (VGDS) meeting. It is not clear how the codevelopment process will affect anticipated FDA/sponsor interactions (with both CDER/CBER and CDRH) meetings, agreements, labeling discussions and post-marketing changes. Clarification is also needed about how joint review and joint meetings will be managed throughout the codevelopment process.
Industry also noted that the life cycle of a drug and diagnostic test are different. Specifically, the life cycle of a diagnostic test involves frequent improvements in the test and platform, post-approval. Also, early development of a partner diagnostic test (validated pre-phase 3) is considered an expensive and high-risk endeavor in those cases when the approvability of the partner drug is uncertain before study in controlled pivotal trials. Industry indicated that it would be useful if the future guidance clarified how life cycle changes will impact the co-developed product's label. In addition, given the clinical utility expectations, industry questioned whether it is possible to add general use indications to the diagnostic test label. Similarly, the comments suggested that the required steps in the review process for follow-on tests should be defined. During the discussion, it was noted that in general diagnostics are not required to show clinical utility in relation to a drug to support regulatory approval. It is not clear to industry why the proposed analytical performance and validation expectations for use with a drug would be different from those in current CDRH guidance.
Some recommended consideration should be given as to developing a decision tree to clarify when co-development is necessary (when a test is required for co-approval) based on efficacy and safety considerations.
B. Regulatory issues
Guidance is needed on how to bridge across technologies in co-developing a diagnostic test assuming a qualified biomarker has been identified, and how this would affect labeling. Interaction of the drug-test review process with other FDA initiatives, including discussions under the provisions of the guidance on Pharmacogenomic Data Submissions, should be clarified. For example, what is the role of advice obtained from the Interdisciplinary Pharmacogenomic Review Group and how will it be integrated into co-development. Clarification is needed for which center or review area would be responsible for the review and approval of the pivotal study for a partner product.
From a regulatory perspective, industry inquired about the possibility of developmental incentives (e.g., exclusivity extensions based on co-development approval) Also, to facilitate development, industry recommend more regulatory acceptance of retrospective data.
There was a general concern that the draft concept paper may represent a higher hurdle for diagnostic approval than current CDRH requirements. It was recommended that future guidance clarifies the usefulness and distinctions between other possible approval pathways for a test that might be used in conjunction with a drug in a codevelopment scenario (i.e., PMA vs CLIA vs IUO vs 510K or de novo 510K). Clarification was requested on the proposed pre-set 'cutoff' or 'indeterminate zone' before pivotal phase 3 studies because in some cases these values may represent a high hurdle for a diagnostic test. Additionally, industry urged inclusion of labeling and cross-labeling considerations including post-marketing changes in future guidance.
both CDER/CBER and CDRH, a pathway to get binding agreement from all parties would be highly desirable.
Next steps
Biomarkers and pharmacogenomic tests may represent critical path milestones for innovative products Conceivably, co-development may lead to enhanced safety or effectiveness of targeted therapies. As the FDA prepares its draft guidance on drug/test co-development, it is anticipated that it will incorporate and consider the stakeholder comments. Before the release of the draft guidance, the FDA encourages industry to take advantage of the voluntary genomic data submission process in order to gain access to the current thinking and regulatory experience pertaining to drug and test co-development. Also, the FDA encourages the therapeutic and diagnostic developers to maintain active intercenter dialogue with both the therapeutic and diagnostics review divisions.
